BioSpace News Archive

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to four new employees.

Quanterix Corporation announced it will host a conference call on Tuesday, February 27, 2024, to discuss its fourth quarter earnings and full year 2023 financial results.

Azitra, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced the closing of its previously announced public offering of 16,667,000 shares of common stock, at a public offering price of $0.30 per share.

Immunome, Inc. announced the closing of its underwritten public offering of 10,000,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,500,000 shares, at a price to the public of $20.00 per share.

Motus GI Holdings, Inc., announced that its special meeting of stockholders held on February 16, 2024 was convened and then adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the proposal described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on January 24, 2024.

Scholar Rock announced that the company granted inducement equity awards covering an aggregate of 131,688 shares of its common stock to four newly hired employees, consisting of inducement stock options to purchase an aggregate of 75,250 shares of common stock and inducement restricted stock units, covering an aggregate of 56,438 shares of its common stock.

Larimar Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 19,736,842 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 2,574,370 additional shares, at the public offering price of $8.74 per share, the closing price of its common stock on February 13, 2024.

Delcath Systems, Inc. announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as a material inducement to the employment of three individuals whose employment commenced in January 2024.

Lucid Diagnostics Inc. a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc., announced that it was notified by the World Trade Center Health Program that, due to a clerical error, the EsoGuard® Esophageal DNA test was incorrectly listed as a covered benefit.

Iovance Biotherapeutics, Inc. announced that on February 15, 2024, the Company approved the grant of inducement stock options covering an aggregate of 40,450 shares of Iovance’s common stock to sixteen new non-executive employees.